NEWS
All News
Special Reports
CONFERENCES
Conference Coverage
Conference Listing
MEDIA
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
PUBLICATIONS
All Publications
Evolving Paradigms
Roundtable Meetings Spotlight
Targeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable Series
Clinical Trials
Partners
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE
eNewsletter

logo
Featured Clinical Focus
AML
BTK Inhibitors: In-Focus
Biomarker-Driven Lung Cancer
Bone Marrow & SCT
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR-Positive Lung Cancer
Endometrial Cancer
Follicular Lymphoma
HCC
Lung Cancer
MPNs
Mantle Cell Lymphoma
Multiple Myeloma
Renal Cell Carcinoma
Small Cell Lung Cancer
Thyroid Cancers
Clinical Focus
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers
Spotlight
Case Based Peer Perspectives
Case-Based Roundtable Series
Clinical Trials
Podcasts
Precision Medicine
Special Reports
All News
Special Reports
Conference Coverage
Conference Listing
All Videos
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Podcasts
Precision Medicine
All Publications
Evolving Paradigms
Roundtable Meetings Spotlight
Targeted Therapies in Oncology
CME/CE
Case-Based Roundtable Series
Clinical Trials
Partners
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
eNewsletter
Advertisement
BONE MARROW & STEM CELL TRANSPLANT
| GYNECOLOGIC CANCERS
| HEMATOLOGY
| LUNG CANCER
| SMALL CELL LUNG CANCER
| THYROID CANCERS
| BRAIN CANCER
| BREAST CANCER
| CAR T-CELL THERAPY
| ENDOMETRIAL CANCER
| GASTRIC CANCER
| GENITOURINARY CANCERS
| GENOMIC TESTING
| GI CANCERS
| HCC
| HEAD & NECK CANCERS
| IMMUNOTHERAPY
| LEUKEMIAS
| LYMPHOMAS
| MET-TARGETED THERAPY
| NTRK GENE FUSIONS
| SARCOMA
| SKIN CANCERS
View All >>
  • BONE MARROW & STEM CELL TRANSPLANT
  • BRAIN CANCER
  • BREAST CANCER
  • CAR T-CELL THERAPY
  • ENDOMETRIAL CANCER
  • GASTRIC CANCER
  • GENITOURINARY CANCERS
  • GENOMIC TESTING
  • GI CANCERS
  • GYNECOLOGIC CANCERS
  • HCC
  • HEAD & NECK CANCERS
  • HEMATOLOGY
  • IMMUNOTHERAPY
  • LEUKEMIAS
  • LUNG CANCER
  • LYMPHOMAS
  • MET-TARGETED THERAPY
  • NTRK GENE FUSIONS
  • SARCOMA
  • SKIN CANCERS
  • SMALL CELL LUNG CANCER
  • THYROID CANCERS

SPOTLIGHT -

Case Based Peer Perspectives
| Case-Based Roundtable Series
| Clinical Trials
| Podcasts
| Precision Medicine
| Special Reports

Alexander Drilon, MD

home / authors / alexander-drilon-md

Articles


FDA-Approved and Investigational TRK Inhibitors

FDA-Approved and Investigational TRK Inhibitors

June 22nd 2022

Alexander Drilon, MD, discusses targeted therapies for the patients with NTRK gene fusion-positive cancers.


Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC

June 6th 2019

Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non–small cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.


Clinical Perspectives in the Evolving Role of Immune-Checkpoint Blockade in Distinct NSCLC Populations

Clinical Perspectives in the Evolving Role of Immune-Checkpoint Blockade in Distinct NSCLC Populations

October 11th 2018

Alexander Drilon, MD, clinical director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, discusses the evolving role of immune-checkpoint blockade in NSCLC.


The Importance of CNS Activity in Agents for NSCLC

The Importance of CNS Activity in Agents for NSCLC

October 20th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of central nervous system (CNS) activity in agents for the treatment of non–small cell lung cancer (NSCLC).

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.